HLB Group Stocks Surge 22-30% Following FDA Lyfigtu Approval
HLB Group stocks continued their rally on May 29, sustaining gains triggered by the US Food and Drug Administration's approval of the anticancer drug Lyfigtu on May 23 (local time). At 10:36 AM on May 29, HLB Pharmaceutical traded at 12,500 won, up 29.94% from the previous trading day, reaching the
GateMacroTradfiHub·09-29 02:21
